Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
Cell Mol Life Sci. 2022 Apr 2;79(4):219. doi: 10.1007/s00018-022-04225-1.
Microglia are specialized dynamic immune cells in the central nervous system (CNS) that plays a crucial role in brain homeostasis and in disease states. Persistent neuroinflammation is considered a hallmark of many neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and primary progressive multiple sclerosis (MS). Colony stimulating factor 1-receptor (CSF-1R) is predominantly expressed on microglia and its expression is significantly increased in neurodegenerative diseases. Cumulative findings have indicated that CSF-1R inhibitors can have beneficial effects in preclinical neurodegenerative disease models. Research using CSF-1R inhibitors has now been extended into non-human primates and humans. This review article summarizes the most recent advances using CSF-1R inhibitors in different neurodegenerative conditions including AD, PD, HD, ALS and MS. Potential challenges for translating these findings into clinical practice are presented.
小胶质细胞是中枢神经系统（CNS）中特化的动态免疫细胞，在脑内稳态和疾病状态中发挥着关键作用。持续的神经炎症被认为是许多神经退行性疾病的标志，包括阿尔茨海默病（AD）、帕金森病（PD）、亨廷顿病（HD）、肌萎缩侧索硬化症（ALS）和原发性进行性多发性硬化症（MS）。集落刺激因子 1 受体（CSF-1R）主要在小胶质细胞上表达，在神经退行性疾病中其表达显著增加。累积的研究结果表明，CSF-1R 抑制剂在神经退行性疾病的临床前模型中可能具有有益的作用。使用 CSF-1R 抑制剂的研究现已扩展到非人类灵长类动物和人类。本文综述了 CSF-1R 抑制剂在不同神经退行性疾病中的最新研究进展，包括 AD、PD、HD、ALS 和 MS。并提出了将这些发现转化为临床实践的潜在挑战。
